is retatrutide a triple agonist Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide: A Triple Agonist Shaping

Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione, cysteamine, and 2-mercaptopropionylglycine in plasma and urine

Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH et al (2025) Body composition changes during weight reduction with Tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight

This dual regulation allows it to maintain appropriate gut blood flow while simultaneously dampening the excessive inflammatory nitric oxide production that worsens intestinal injury

It has been clinically demonstrated that the activation of the GLP-1R suppresses cardiovascular and renal events and that the suppression of the endogenous action of incretin by antibodies may have increased the occurrence of these events, as well as the associated mortality

The important clinical point is that these two pathways are synergistic